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Abstract  WHO  grade  II  gliomas  are  a  major  challenge  for  magnetic  resonance  imaging  (MRI)
due to  their  delayed  anaplastic  transformation.  Today  it  is  possible  to  individually  characterize
tumor progression  from  diagnosis  to  anaplastic  transformation  based  on  the  many  parameters
identiﬁed  in  studies  in  the  literature  and  the  possibility  of  integrating  these  data  into  mathe-
matical models.  Early  identiﬁcation  of  negative  morphological  and  metabolic  factors,  as  well  as
treatment  follow-up,  help  identify  predictive  factors  of  tumor  progression,  as  well  as  determinefollow-up treatment  response  to  adapt  management  of  this  disease.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.At  present  MRI  is  the  ﬁrst  line  imaging  technique  for  the  non-invasive  exploration  of
intracranial  tumor  progression.  Nevertheless,  the  sensitivity  and  speciﬁcity  of  existing
MRI  protocols  are  limited  [1,2].  According  to  the  WHO  classiﬁcation,  grade  II  gliomas,
also  called  low-grade  gliomas  (LGG),  express  atypical  nuclei  and  inevitably  progress  at  a
rate  that  varies  from  one  case  to  another.  In  the  last  decade,  the  pre-therapeutic  char-
acterization  of  these  tumors  has  improved  signiﬁcantly  thanks  to  advances  in  imaging
techniques.  Thus,  MR  spectroscopy  (which  is  essentially  protonic)  and  dynamic  perfusion
imaging  have  helped  improve  the  speciﬁcity  and  sensitivity  of  MRI  for  the  diagnosis  and
follow-up  of  gliomas  (Fig.  1).  Tumor  volume,  relative  cerebral  blood  volume  and  MR  spec-
troscopy  results  have  also  provided  predictive  factors  of  disease  progression  or  response
to  treatment,  while  other  MRI  parameters  are  correlated  to  molecular  proﬁles.
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spectroscopy  using  separation  spectral  editing,  a  tool  that  is58  
mproving the diagnostic accuracy: how
ggressive is a WHO grade II (OK?) tumor?
rom  diagnosis  to  prognosis.  Diffuse  low-grade  gliomas  (WHO
rade  II  gliomas,  LGG)  are  heterogenous  on  MRI.  These
nﬁltrating  tumors  have  ill-deﬁned  margins  on  T2-weighted
hyperintense)  as  well  as  T1-weighted  (hypointense)  images
nd  usually  have  no  contrast  enhancement  following
adolinium  injection.  When  enhancement  occurs,  in  10  to
0%  of  the  cases  depending  on  the  series,  it  is  moderate
nd  only  in  a  small  portion  of  the  tumor.  The  prognostic
alue  of  this  event  is  still  a  subject  of  debate  [3,4].  Only
learly  nodular-shaped  tumors  and  time-progressive  tumor
nhancement  have  been  shown  to  have  a  negative  progno-
tic  value  [5].  Moreover,  there  is  signiﬁcant  intraobserver
ariability  as  well  as  an  inter-institutional  heterogeneity  of
arameters  depending  on  the  magnetic  ﬁeld  and  the  types
f  sequences  obtained.  T1-weighted  spin  echo  sequences
ave  been  shown  to  be  better  than  gradient-echo  sequences
6,7].  Recent  studies  have  shown  that  diffusion  imaging
ith  ADC  variations  is  better  at  identifying  anaplastic
igure 1. Is this a low-grade glioma? (a) Heterogeneous gadolinium en
oderately increased with the presence of lactate resonance. The rCBV
rontal lobe tumor on all sequences, no gadolinium enchancement. The
nd the rCBV is 3.5. WHO grade II glioma, Ki-67 index 12%.
n
v
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ransformation  in  progressive  LGG  [8]. The  1p/19q  co-
eletion  can  be  conﬁrmed  by  quantifying  texture  [9].
everal  correlations  have  been  established  between  proton
pectroscopy  and  pathology,  immunohistology  and  molecu-
ar  biology,  and  some  of  these  criteria  are  considered  to  be
redictive  of  anaplastic  transformation  of  LGG.  Thus,  there
s  a  correlation  with  the  Cho/Cr  index  (all  levels).  More
ecently,  speciﬁc  spectral  patterns  for  a  range  of  Ki-67  val-
es  have  been  established  for  LGG  [10]. Thus,  the  presence
f  increased  lactate  resonance,  indicative  of  underlying
naerobiosis,  is  predictive  of  a  Ki-67  index  of  4  to  8%  (Fig.  2).
ater,  membrane  alterations  result  in  resonance  of  mobile
ipids,  which  is  correlated  to  atypical  cells  and  predictive  of
 Ki-67  index  of  above  8%  (Figs.  1  and  2).  Thus,  the  results  of
‘spectroscopic’’  analysis  suggest  that  there  is  a critical  Ki-
7  threshold  value.  Similarly,  indirect  identiﬁcation  of  the
DH  mutation  based  on  2  hydroxyglutarate  resonance  on  MRchanced right parietal rolandic tumor. On MR spectroscopy, CNI is
 is 1.6. WHO grade II glioma with Ki-67 index = 4%. (b) Homogenous
 CNI is much higher here with mobile lipids and lactate resonance
ow  available  in  some  centers,  has  diagnostic  and  predictive
alue  [11]. Multinuclear  MR  spectroscopy,  and  in  particular
1P  phosphorus  spectroscopy,  can  also  be  used  to  investigate






























rFigure 2. What is the sub-grade? The spectral pattern predicts a
index of between 4 and 8%, while mobile lipid resonance predicts a
the  natural  history  of  LGG.  A  2012  study  [12],  showed  that
the  PME/PDE  ratio  and  the  pHi  value  were  elevated  in  LGG
with  a  Ki-67  above  8%,  results  that  have  already  been  shown
to  be  pro-anaplastic  factors  in  experimental  studies  [13].
Metabolic changes and increased perfusion
Numerous  studies  have  shown  the  value  of  perfusion  imag-
ing  for  the  initial  characterization  and  follow-up  of  LGG.
An  increase  in  rCBV  values  precedes  T1-weighted  post-
gadolinium  tumor  enhancement,  sometimes  by  a  few  months
[14].  Initial  rCBV  values  above  1.7  were  negatively  corre-
lated  to  survival  and  predictive  of  progression-free  survival
that  was  4  to  5  times  lower  than  in  patients  with  rCBV
values  below  1.7  [15,16].  However,  discrimination  between
oncotypes  remains  controversial.  Indeed,  although  a  certain
difference  has  been  found  in  the  rCBV  between  oligoden-
drogliomas  and  astrocyctomas  in  some  studies,  it  was  not
signiﬁcant  and  varied  considerably  depending  on  the  study
[17—19].  This,  as  well  as  the  poor  reproducibility  of  rCBV
values  between  1.5  and  3  Tesla  machines,  may  represent  a
potential  weakness  of  perfusion  imaging,  which  is  too  often
performed  alone  as  an  ‘‘advanced  imaging  technique’’  (i.
e.  without  MR  spectroscopy)  [20].  Capillary  permeability,
which  can  be  determined  on  T1-  and  T2-  weighted  per-
fusion  imaging  (k  Trans  and  K2),  could  provide  early  proof
of  progression  of  low-grade  gliomas  [21].  The  maximum
rCBV  value  was  positively  correlated  with  choline  reso-
nance,  which  increased  with  tumor  progression  [22].  Our
team  showed  that  the  CNI,  as  well  as  Lac/Cr  and  Lip/Cr
ratios,  were  independent  predictive  factors  of  the  maxi-
mum  rCBV  [16].  Moreover,  these  two  ratios  discriminated
between  patient  survival  in  the  two  groups  based  on  the




te of values for the Ki-67 index. Lactate resonance predicts a Ki-67
7 index above 8%.
mphasizes  the  importance  of  combining  proton  MR
pectroscopy  and  dynamic  perfusion  imaging,  two  comple-
entary  techniques,  for  the  initial  assessment  and  follow-up
f  low-grade  gliomas.
ost-therapeutic follow-up
or  several  years,  long-term  volumetric  measurement  of
umor  size  has  been  considered  to  be  the  simple,  most
ffective  tool  for  treatment  follow-up.  The  average  trans-
erse  diameter  (ATD)  is  determined  on  T2-weighted  images
most  often  FLAIR  images).  However,  this  morphological
arameter  must  be  monitored  for  at  least  six  months  to
btain  a  reliable  indication  of  tumor  progression.  Moreover,
ome  studies  [23,24]  have  suggested  that  chemotherapy
ould  induce  metabolic  alterations  in  the  tumor  with  no
erceptible  changes  in  morphological  features  or  standard
RI  signals.  Thus,  the  response  to  chemotherapy  could  be
ncorrectly  considered  to  be  lacking  or  delayed,  because  it
s  evaluated  by  morphological  imaging  only,  which  is  usu-
lly  the  case.  Proton  MR  spectroscopy  has  been  shown  to
e  useful  for  the  short-term  assessment  of  chemotherapy,
nce  again  conﬁrming  its  complementarity  with  standard
RI  [25,26].  Thus,  one  study  [27]  showed  that  modiﬁcations
ould  be  observed  on  monovoxel  proton  MR  spectroscopy
s  early  as  the  ﬁrst  month  after  treatment  with  temozolo-
ide,  while  changes  in  tumor  volume  were  slight  and  barely
erceptible  by  the  radiologist.  An  easily  quantiﬁable,  sig-
iﬁcant  and  concomitant  decrease  in  Cho/Cr  and  Cho/Naa
atios  was  observed  in  responders,  indicating  the  direct
etabolic  effect  of  temozolomide  on  tumor  anaplasia  [28].
urthermore,  in  patients  with  secondary  escape  from  treat-
ent  during  the  study,  an  event  that  is  clearly  seen  on  the
reatment  follow-up  curve  (Fig.  3),  preceded  the  change  in
960  R.  Guillevin  et  al.
















































tent. Despite a slight decrease in tumor volume which is barely det
atios shows clear, objective variations corresponding to a therapeu
umor  volume  by  one  or  two  months.  These  data  suggest
hat  a  change  in  treatment  could  be  planned.  Finally,  after
hree  months  of  treatment,  it  is  possible  to  predict  a  tumor
esponse  (relative  mean  decrease  in  Cho/CR),  or  an  ‘‘escape
rom  treatment’’  at  14  months  (relative  mean  decrease  in
ho/CR  and  Cho/Naa).  This  correlation  between  tumor  vol-
me  and  MR  spectroscopy,  in  particular  over  time,  seems  to
e  particularly  important  with  temozolomide,  due  to:
the  importance  of  this  drug  in  the  treatment  options  of
LGG  as  well  as;
the  wide  range  of  response  rates  reported  in  numerous
studies  in  the  literature  [29,30].
Another  difﬁculty  in  the  follow-up  of  low-grade  gliomas
s  evaluation  of  the  results  of  radiation  therapy.  Standard
RI  often  fails  to  distinguish  between  radiation  necro-
is  and  tumor  recurrence.  ‘‘Soap  bubble’’  or  especially
‘swiss  cheese’’  enhancement  on  T1-weighted  gadolinium
nhanced  images  does  not  provide  a  differential  diagnosis
31].  However,  the  diagnostic  speciﬁcity  had  improved  in
ore  recent  MRI  sequences.  Thus,  the  increased  cellularity
f  recurrent  tumors  generates  low  ADC  values  on  diffusion-
eighted  imaging  (DWI).  However,  numerous  post-radiation
ffects  could  interfere  with  this  diagnosis.  A  threshold  of
.6  for  rCBV  max  seems  to  be  a  good  indication  of  tumor
ecurrence,  like  a  combination  of  the  Cho.Cr  and  Cho/Naa
hresholds  in  which  the  sensitivity  and  speciﬁcity  of  results
ere  clearly  improved  by  combining  at  least  two  parameters
33].  Finally,  Amide  Proton  Transfer  (APT)  is  a  novel  molec-




Ile with volumetric analysis, the comparison of the CNI and Cho/Cr
esponse.
rogressive  glioma  is  hyperintense  on  APT  sequences  while
adiation  necrosis  is  hypointense  [34]).
odels to improve understanding
s  mentioned  above,  there  are  intracranial  MRI  results  from
ore  than  twenty  studies,  making  global  analysis  of  these
ata  difﬁcult.  How  can  these  parameters  be  integrated  into
 coherent  whole?  Two  approaches  have  been  suggested  in
he  past  few  years.
The  ﬁrst  approach  is  based  on  the  simple  observation  of
he  millimetric  spatial  resolution  of  MR  spectroscopic  images
o  obtain  a  tumor  volume  growth  curve.  This  is  then  included
n  a mathematical  model  to  characterize  individual  tumor
ynamics.  The  proliferation-diffusion  equation  takes  into
ccount  both  tumor  growth  and  parenchymal  inﬁltration  via
he  diffusion  of  tumor  cells  resulting  in  a  new  parameter
ith  a  strong  prognostic  value.
The  second  approach  analyzes  the  metabolic  changes  in
ow-grade  gliomas  that  precede  the  morphological  changes
uring  the  sometimes  long  progression  of  this  disease,
n  particular  using  MR  spectroscopy  and  perfusion.  Tumor
etabolism  adjusts  to  growing  hypoxia  by  modifying  lac-
ate  transporters  and  increasing  anaerobic  glycolysis.  This
iomathematical  model,  which  has  been  described  in  sev-
ral  articles,  deﬁnes  several  LGG  subtypes,  including  certain
hat  represent  an  borderline  between  WHO  grade  II  and
II  gliomas,  and  whose  detection  during  follow-up  can  be
961
• There  are  correlations  between  multiparametric  MRI
and  immunohistochemistry  results.
• There  are  correlations  between  multiparametric  MRI
and  molecular  biology  results.
• Tumor  volumetrics,  perfusion  imaging,  and  MR
spectroscopy  are  complementary  tests  for  the
intermediate  and  short-term  follow-up  of  LGG.
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especially  important  for  therapeutic  management  of  these
tumors  [35].
Conclusion
Conceptually,  gliomas  should  now  be  considered  a  dynamic
multiparametric  entity.  Indeed,  the  progression  of  MR  spec-
troscopic  features  over  time  conﬁrms  the  importance  of
monitoring  tumor  progression  with  this  imaging  technique.
This  has  created  new  problems  associated  with  repro-
ducibility  (intra-  and  inter  center)  of  tests,  which  must
be  performed  on  the  same  machine  in  the  same  patients
while  avoiding  comparison  of  results  of  certain  sequences
obtained  from  1.5  and  3  Tesla  machines.  Sequences  should
also  be  read  and  treated  on  the  same  console  with  the  same
software.  Finally,  the  results  of  these  tests  and  patient  ﬁles
should  be  discussed  in  national  multidisciplinary  meetings.
TAKE-HOME  MESSAGES
• Multiparametric  MRI  plays  an  essential  role  in  the
initial  assessment  of  low-grade  gliomas  because
it  provides  information  on  tumor  aggressivity  and
potential  progression  in  young  adults  even  before
biopsy.
5
Figure 4. Multiparametric ﬁle of a glioma in the left temporoparie
resonance. The rCBV is 2.23.tumor  progression  for  individual  patients.
linical case
 31-year-old  man  was  referred  to  the  radiology  unit  for  MRI
o  assess  an  initial  epileptic  crisis  (Fig.  4).  Results  showed
 tumor  in  the  left  temporoparietal  junction  with  standard
RI,  features  suggesting  low-grade  glioma.
uestions
)  What  are  the  arguments  to  support  this  diagnosis?
)  Multiparametric  imaging  results  identify  certain  patho-
logical  features;  what  are  they?
)  What  is  the  prognostic  value  of  an  increase  in  rCBV?
)  Is  the  presence  of  T1-weighted  gadolinium  enhancement
a  negative  predictive  factor?
)  What  is  the  most  reliable  MRI  marker  of  short  and  inter-
mediate  term  tumor  progression?




























)  A  fairly  homogenous  tumor  on  all  sequences,  with  unde-
ﬁned  margins,  little  or  no  gadolinium  enhancement  and
no  necrotic  cavitation  or  hemorrhageic  changes.
)  Elevated  CNI,  mobile  lipids  and  lactate  resonance.  Mobile
lipid  resonance  is  predictive  of  a  Ki-67  above  8%,  an  ele-
vated  value  for  this  grade  tumor.  Lactate  resonance  is
predictive  of  an  rCBV  above  1.7,  which  is  indeed  the  case.
)  Signiﬁcantly  reduced  progression-free  survival  because
this  value  is  above  1.7,  which  is  the  case.
)  No,  not  alone  because  this  is  the  case  in  20  to  30%  of
LGG,  regardless  of  the  prognosis.  Only  the  presence  of
T1-weighted  gadolinium  enhancement  during  follow-up
can  be  considered  a  marker  of  tumor  progression.
)  The  average  transverse  diameter  obtained  from  tumor
volumetrics.
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